 SAN CLEMENTE, CA ACCESSWIRE May 17, 2021 ReShape Lifesciences Inc. OTCQB:RSLS, a leading developer and distributor of minimally invasive medical devices to treat obesity and metabolic diseases, today reported its financial and operational results for the three months ended March 31, 2021. Recent Highlights and Accomplishments Increased revenues by 15.5 compared to same period in 2020 Increased revenues by 4.6 compared to non COVID-19 pandemic affected same period in 2019 Continued to implement previously mentioned cost savings plan reducing operating expenses by 1.1 million Improved Non-GAAP loss by 1.6 million Obtained 15.0 million line of credit with instutional investor Received full forgiveness of 1.0 million on PPP loan 2021 has proven to be a transformational year for Reshape, as we continue on our pathway to becoming the premier physician led weight loss company, said Bart Bandy, President, and Chief Executive Officer at ReShape Lifesciences. 